Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) Director Peter Thornton bought 5,155 shares of the business’s stock in a transaction that occurred on Thursday, September 21st. The stock was purchased at an average cost of $9.74 per share, for a total transaction of $50,209.70. Following the completion of the transaction, the director now directly owns 5,155 shares in the company, valued at approximately $50,209.70. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Avadel Pharmaceuticals PLC. (NASDAQ AVDL) traded up 4.09% during trading on Wednesday, reaching $11.19. 121,937 shares of the company’s stock were exchanged. The company’s 50-day moving average is $9.30 and its 200-day moving average is $9.78. The company has a market capitalization of $448.54 million, a PE ratio of 12.16 and a beta of 1.47. Avadel Pharmaceuticals PLC. has a 1-year low of $8.14 and a 1-year high of $13.25.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.14. Avadel Pharmaceuticals PLC. had a net margin of 21.13% and a return on equity of 29.84%. The company had revenue of $46.30 million for the quarter, compared to analyst estimates of $45.17 million. The business’s quarterly revenue was up 19.0% on a year-over-year basis. Equities research analysts expect that Avadel Pharmaceuticals PLC. will post $1.16 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/flamel-technologies-s-a-avdl-director-acquires-50209-70-in-stock/1587697.html.

A number of brokerages have commented on AVDL. Zacks Investment Research cut Avadel Pharmaceuticals PLC. from a “hold” rating to a “sell” rating in a research note on Monday, August 7th. Langenberg & Company reiterated a “buy” rating and set a $30.00 target price (up from $27.00) on shares of Avadel Pharmaceuticals PLC. in a report on Thursday, September 7th. Ladenburg Thalmann Financial Services raised their target price on Avadel Pharmaceuticals PLC. from $27.00 to $30.00 in a report on Thursday, September 7th. Finally, Roth Capital set a $15.00 price target on Avadel Pharmaceuticals PLC. and gave the stock a “buy” rating in a research report on Wednesday, August 9th.

A number of institutional investors and hedge funds have recently made changes to their positions in AVDL. State Street Corp lifted its position in Avadel Pharmaceuticals PLC. by 1.7% during the 2nd quarter. State Street Corp now owns 31,782 shares of the company’s stock worth $351,000 after acquiring an additional 523 shares during the last quarter. Stifel Financial Corp grew its position in shares of Avadel Pharmaceuticals PLC. by 4.3% in the second quarter. Stifel Financial Corp now owns 60,500 shares of the company’s stock valued at $667,000 after purchasing an additional 2,500 shares during the last quarter. Sei Investments Co. grew its position in shares of Avadel Pharmaceuticals PLC. by 29.5% in the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after purchasing an additional 2,900 shares during the last quarter. Trexquant Investment LP grew its position in shares of Avadel Pharmaceuticals PLC. by 30.7% in the second quarter. Trexquant Investment LP now owns 30,500 shares of the company’s stock valued at $336,000 after purchasing an additional 7,169 shares during the last quarter. Finally, Columbus Circle Investors grew its position in shares of Avadel Pharmaceuticals PLC. by 16.7% in the second quarter. Columbus Circle Investors now owns 51,137 shares of the company’s stock valued at $564,000 after purchasing an additional 7,315 shares during the last quarter. Hedge funds and other institutional investors own 69.09% of the company’s stock.

Avadel Pharmaceuticals PLC. Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Insider Buying and Selling by Quarter for Avadel Pharmaceuticals PLC. (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.